Shares of Chiasma Inc (NASDAQ:CHMA) have been given a consensus rating of “Buy” by the six ratings firms that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $9.90.
CHMA has been the subject of several recent research reports. ValuEngine raised Chiasma from a “hold” rating to a “buy” rating in a report on Tuesday, March 5th. Cantor Fitzgerald initiated coverage on Chiasma in a research report on Thursday, March 7th. They issued an “overweight” rating and a $5.84 price objective on the stock. Zacks Investment Research downgraded Chiasma from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. Roth Capital initiated coverage on Chiasma in a research report on Tuesday, February 19th. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Chiasma in a research report on Thursday, June 6th.
NASDAQ:CHMA opened at $7.82 on Wednesday. Chiasma has a 52-week low of $1.20 and a 52-week high of $8.29. The stock has a market cap of $250.97 million, a price-to-earnings ratio of -6.11 and a beta of 1.22.
Chiasma (NASDAQ:CHMA) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.02). On average, equities research analysts expect that Chiasma will post -1.14 EPS for the current fiscal year.
In other news, Director Roni Mamluk sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $5.31, for a total value of $53,100.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $53,100. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.20% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in CHMA. Vanguard Group Inc. lifted its holdings in shares of Chiasma by 42.8% during the 3rd quarter. Vanguard Group Inc. now owns 324,625 shares of the biotechnology company’s stock valued at $1,169,000 after purchasing an additional 97,272 shares during the last quarter. Vanguard Group Inc grew its position in Chiasma by 42.8% during the 3rd quarter. Vanguard Group Inc now owns 324,625 shares of the biotechnology company’s stock worth $1,169,000 after purchasing an additional 97,272 shares during the period. Acadian Asset Management LLC grew its position in Chiasma by 99.1% during the 4th quarter. Acadian Asset Management LLC now owns 22,647 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 11,273 shares during the period. Dimensional Fund Advisors LP grew its position in Chiasma by 20.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 97,644 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 16,658 shares during the period. Finally, Millennium Management LLC acquired a new stake in Chiasma during the 4th quarter worth about $41,000. Institutional investors and hedge funds own 62.78% of the company’s stock.
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Recommended Story: Rule of 72
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.